Small molecule inhibitors of angiogenesis including regorafenib, sunitinib, and lenvatinib showed response rates ranging from 0% to 38% in patients with advanced thymic carcinoma The following emerging drug targets are under evaluation in thymic epithelial tumors: the mediator of nucleus‐cytoplasmic shuttling XPO1; the PI3K/mTOR pathway; the CDK/Rb pathway; NTRK 1/2/3, and the MTAP enzyme.27 The gene discussed is XPO1; the disease is thymic carcinoma.